drugset / Trial / NCT03503864
Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial aims to explore and evaluate the efficacy and safety of combined chemotherapy with arsenic trioxide for stage 4/M neuroblastoma.
Timeline
- Start
- 2017-06-12
- Primary completion
- 2023-08-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | arsenic trioxide | Small molecule | 0.16 mg/kg | Intravenous |